Vigil Neuro
Alysia Martins is a skilled professional with a strong background in biomedical research and engineering. Currently serving as a Principal Research Associate at Vigil Neuroscience since June 2023, Alysia previously held positions as a Research Associate II at Cognesy Therapeutics and a Research Associate at the Lieber Institute for Brain Development. Experience includes extensive work in neural tracing and immunohistochemistry at The Johns Hopkins University School of Medicine, where Alysia was also a Study Consultant and Research Assistant. Early career roles include consulting on oncology cell therapies at Alera Partners and contributing software engineering skills at Accenture. Alysia's academic credentials include a Master's degree in Bioengineering and Biomedical Engineering from Johns Hopkins Whiting School of Engineering and a Bachelor's degree in Biotechnology from RV College of Engineering.
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.